Evaluation of recurrence rate in Canadian patients with stage II/III HR+/HER2-early breast cancer in the real-world setting

被引：0
|
作者：
Marques, Maud
Gambaro, Karen
Basik, Mark
Saad, Fred
Hassan, Saima Noor
Boudreau, Dominique
Vincent, Francois
St-Hilaire, Eve
Mackay, Helen
Abdelsalam, Mahmoud
Guillemette, Stephanie
Leite, Ricardo
Caron, Marc-Andre
Patel, Chandni
Batist, Gerald
机构：
[1] Exactis Innovat, Montreal, PQ, Canada
[2] Segal Canc Ctr, Montreal, PQ, Canada
[3] Univ Montreal, Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[4] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[5] Hop St Sacrement, Quebec City, PQ, Canada
[6] Ctr Integr Univ Sante & Serv Sociaux, Mauricie Ctr Quebec, Trois Rivieres, PQ, Canada
[7] Ctr Oncol Leon Richard, Moncton, NB, Canada
[8] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
[9] Moncton City Hosp, Moncton, NB, Canada
[10] Novartis Pharmaceut Canada Inc, Dorval, PQ, Canada
[11] Novartis Canada, Toronto, ON, Canada
[12] Novartis Corp, Montreal, PQ, Canada
[13] Jewish Gen Hosp McGill, Segal Canc Ctr, Montreal, PQ, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e23303
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Real-World Observational Study of Incidence and Outcomes in an HR+/HER2- Early Breast Cancer Population with High-Risk of Recurrence in Finland
    Singh, Ravinder
    Tuominen, Samuli
    Lassenius, Mariann I.
    Auvinen, Merja
    Torstensson, Astrid
    Wiklund, Tom
    ONCOLOGY AND THERAPY, 2025, 13 (01) : 185 - 200
  • [22] Factors associated with distant recurrence (DR) risk in patients (pts) with HR+/HER2-early breast cancer (EBC): a machine learning (ML) model-based analysis using real-world (RW) data
    Sparano, J. A.
    Lustberg, M. B.
    de Nonneville, A.
    Bachelot, T.
    Santa-Maria, C. A.
    Blyuss, O.
    Fasching, P. A.
    Brezden-Masley, C.
    Park, Y. H.
    Akdere, M.
    Ye, F.
    Pattipaka, T.
    Manneni, V. R.
    Kurz, C.
    Castro, P. Dominguez
    Howard, F. M.
    BREAST, 2025, 80
  • [23] Abemaciclib for treating patients with HR+, HER2-advanced/metastatic breast cancer in Spain: a real-world study
    Blancas, I.
    Fakhouri, W.
    Molero, A.
    Diaz-Cerezo, S.
    Haro, J. M.
    Faris, L. H.
    Sanchez-Bayona, R.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S59 - S60
  • [24] The Role of Ki-67 in HR+/HER2-Breast Cancer: A Real-World Study of 956 Patients
    Ma, Qin
    Liu, Yao-Bang
    She, Tong
    Liu, Xin-Lan
    BREAST CANCER-TARGETS AND THERAPY, 2024, 16 : 117 - 126
  • [25] Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review
    Christiansen, Emilie Adrian
    Kuemler, Iben
    FUTURE SCIENCE OA, 2024, 10 (01):
  • [26] Impact of clinical characteristics, patients' perception of treatment goals and endocrine therapy history on HRQOL in HR+, HER2-early stage breast cancer patients
    Williams, R.
    Brown, J.
    Rider, A.
    Wild, R.
    Clayton, E.
    Method, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S336 - S336
  • [27] Patient-reported outcomes among patients with HR+/HER2-early breast cancer: A systematic literature review
    Salvo, E. M.
    Cueto, J.
    Law, E. H.
    Da Silva, C. Aniceto
    Cameron, C.
    Samjoo, I. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S45 - S46
  • [28] Treatment Patterns and Health Resource Utilization in Patients With HR+/ HER2- Locally Advanced or Metastatic Breast Cancer in Real-World Setting in Taiwan
    Novick, Diego
    Rajan, Narayan
    Wei, Alice
    Cheng, Rebecca
    Colman, Sam
    Szende, Agota
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 36 : 98 - 104
  • [29] Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2-Early Breast Cancer
    Kwon, Mi Jeong
    Ryu, Jai Min
    Cho, Soo Youn
    Nam, Seok Jin
    Kim, Seok Won
    Lee, Jeeyeon
    Lee, Soo Jung
    Park, Ji-Young
    Park, Ho Yong
    Hong, Sungjun
    Kim, Kyunga
    Han, Jinil
    Moon, Youngho
    Shin, Young Kee
    Lee, Jeong Eon
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [30] The prediction of Oncotype DX risk group using clinicopathologic factors in patients with HR+/HER2-early breast cancer
    Song, R.
    Lee, D. -E.
    Lee, S.
    Kang, H. -S.
    Han, J. H.
    Lee, K. S.
    Sim, S. H.
    Chae, H.
    Kwon, Y.
    Woo, J.
    Lee, M.
    Lee, E. -G.
    Jung, S. -Y.
    BREAST, 2023, 68 : S74 - S75
12345